Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
Search
08
2024-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
25
2024-03
Annual Results Announcement for the Year Ended 31 December 2023
12
2024-03
Notice of Board Meeting
08
2024-03
Voluntary Announcement Phase 3 Clinical Trial Completed in China for Dulaglutide Injection (BA5101) and BLA to be Filed
01
2024-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
29
2024-02
Notification Letter to Non-registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
29
2024-02
Notification Letter to Registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
01
2024-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
30
2024-01
Voluntary Announcement Authorization to Zencore Biologics to use BA-HIEXcell Stable Cell Line Development Platform
26
2024-01
Voluntary Announcement Exclusive License Agreement for BA2101 in the Treatment of Respiratory System Diseases
3
4
5
6
7
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
